Hartmann Anke, Schmidt-Habel Anne, Löhberg Lisa, Zajitschek Jörg, Englbrecht Matthias, Eichner Saskia, Schuler Gerold
Department of Dermatology, University Hospital Erlangen, Ulmenweg 18 91054 Erlangen, Germany.
Department of Internal Medicine and Institute of Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Eur J Dermatol. 2014 Sep-Oct;24(5):551-9. doi: 10.1684/ejd.2014.2398.
Targeted UVB intense pulsed light (IPL)-phototherapy has gained interest for repigmentation of vitiligo as it allows selective treatment, sparing the surrounding skin. However, optimal treatment frequency and duration are not known.
We compared the efficacy and safety of two treatment protocols, weekly and every two weeks, for a maximum of 12 months. Variables affecting treatment response were evaluated.
PATIENTS & METHODS: 22 patients (16 female, 6 male; aged 15 - 67 years) with generalised vitiligo were evaluated retrospectively. UVB-IPL had been administered weekly (13 patients, group A), or every second week (9 patients, group B). In cases of no response, treatment stopped after 6 months. Regimentation was evaluated qualitatively and quantitatively.
After 6 months, 12/13 patients (A), 3/9 patients (B) showed repigmentation. Due to lack of success, treatment was stopped after 6 months in 1 group A patient and 6/9 group B patients. After 12 months, lesions on the face and trunk in group A showed a mean of 70 ± 27% and 60 ± 29% repigmentation, respectively. Moderate to good repigmentation was seen in 78% of group A patients on the ulnar region on the forearms and the shins. Side effects were minimal. Treatment success depended on treatment frequency, number of treatments and the anatomical site of lesions.
UVB-IPL phototherapy seems to be effective and well-tolerated in non-segmental vitiligo. A treatment frequency of weekly intervals rather than every two weeks appears preferable. Our observations will help in designing a sufficiently powered prospective clinical trial to test this hypothesis.
靶向窄谱中波紫外线(UVB)强脉冲光(IPL)光疗因可实现选择性治疗、避免周围皮肤受照,在白癜风复色治疗中受到关注。然而,最佳治疗频率和疗程尚不清楚。
我们比较了两种治疗方案(每周一次和每两周一次,最长治疗12个月)的疗效和安全性。评估了影响治疗反应的变量。
对22例泛发性白癜风患者(16例女性,6例男性;年龄15 - 67岁)进行回顾性评估。UVB-IPL治疗方案为每周一次(13例患者,A组)或每两周一次(9例患者,B组)。若无效,6个月后停止治疗。对色素恢复情况进行定性和定量评估。
6个月后,A组12/13例患者、B组3/9例患者出现色素再生。因治疗未成功,1例A组患者和6/9例B组患者在6个月后停止治疗。12个月后,A组患者面部和躯干皮损的色素再生平均分别为70±27%和60±29%。A组78%患者前臂尺侧和胫部色素再生为中度至良好。副作用极小。治疗成功取决于治疗频率、治疗次数和皮损的解剖部位。
UVB-IPL光疗在非节段型白癜风中似乎有效且耐受性良好。每周一次的治疗频率似乎优于每两周一次。我们的观察结果将有助于设计一项有足够效力的前瞻性临床试验来验证这一假设。